Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?

Haoyue Guo; Lishu Zhao; Junjie Zhu; Peixin Chen; Hao Wang; Minlin Jiang; Xiaogang Liu; Hui Sun; Wencheng Zhao; Zixuan Zheng; Wei Li; Bin Chen; Qiyu Fang; Menghang Yang; Yayi He; Yang Yang

doi:10.1016/j.semcancer.2021.05.025

Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?

Semin Cancer Biol. 2022 Nov;86(Pt 2):1190-1206. doi: 10.1016/j.semcancer.2021.05.025. Epub 2021 May 21.

Authors

Haoyue Guo¹, Lishu Zhao², Junjie Zhu³, Peixin Chen¹, Hao Wang¹, Minlin Jiang¹, Xiaogang Liu³, Hui Sun², Wencheng Zhao², Zixuan Zheng⁴, Wei Li², Bin Chen², Qiyu Fang², Menghang Yang², Yayi He⁵, Yang Yang⁶

Affiliations

¹ Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China; Tongji University, No 1239 Siping Road, Shanghai, 200092, People's Republic of China.
² Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China.
³ Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
⁴ Tongji University, No 1239 Siping Road, Shanghai, 200092, People's Republic of China; Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
⁵ Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China; Tongji University, No 1239 Siping Road, Shanghai, 200092, People's Republic of China. Electronic address: yayi.he@tongji.edu.cn.
⁶ Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China; School of Materials Science and Engineering, Tongji University, Shanghai, 201804, People's Republic of China. Electronic address: timyangsh@tongji.edu.cn.

PMID: 34029741
DOI: 10.1016/j.semcancer.2021.05.025

Abstract

Lung cancer is the top reason for cancer-related deaths worldwide. The 5-year overall survival rate of lung cancer is approximately 20 % due to the delayed diagnosis and low response rate to regular treatments. Microbiota, both host-microbiota and alien pathogenic microbiota, have been investigated to be involved in a complicated and contradictory relationship with lung cancer initiation, treatments, and prognosis. Disorders of certain host-microbiota and pathogen infection are associated with the risk of lung cancers based on epidemiological evidence, and antibiotics (ATBs) could dramatically impair anti-cancer treatment efficacy, including chemotherapy and immunotherapy. Moreover, probiotics and microbe-mediated drugs are potential approaches to enhance regular anti-tumor treatments. Therefore, the knowledge of the complex dual effect of microbes on lung cancer is beneficial to take their essence and remove their dross. This review offers insight into the current trends and advancements in microbiota or microbial components related to lung cancer.

Keywords: Chemotherapy; Early detection of cancer; Immunotherapy; Lung cancer; Microbiota.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy
Lung Neoplasms* / drug therapy
Lung Neoplasms* / etiology
Microbiota*
Probiotics* / therapeutic use
Prognosis